X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, Aditxt will acquire Appili along with its pipeline, which includes the ATI-1701 vaccine. Currently, the vaccine is undergoing evaluation in preclinical trials for the treatment of tularemia.
Lead Product(s): ATI-1701
Therapeutic Area: Infections and Infectious Diseases Product Name: ATI-1701
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: Appili Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 02, 2024
Details:
Through the acquisition of Evofem, Aditxt gains access to its first and only FDA-approved hormone-free contraceptive gel, Phexxi (lactic acid, citric acid, and potassium bitartrate).
Lead Product(s): L-Lactic Acid,Citric Acid,Potassium Bitartrate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Phexxi
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Evofem Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 12, 2023
Details:
Under the agreement, Aditxt expands its portfolio to include innovative therapies for infectious diseases by including Avigan (favipiravir), an oral broad-spectrum inhibitor of viral RNA-dependent RNA polymerase.
Lead Product(s): Favipiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Avigan
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cellvera
Deal Size: $10.0 million Upfront Cash: $10.0 million
Deal Type: Agreement April 20, 2023
Details:
ADI™-100 consists of two DNA molecules, which together restore immune tolerance in autoimmune disease and establish tolerance in allogeneic skin transplantation applied in large skin wounds.
Lead Product(s): ADI-100
Therapeutic Area: Dermatology Product Name: ADI-100
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2022
Details:
The company intends to use the net proceeds for general corporate purposes, which may include research and development expenses for plasmid DNA-based therapeutics, capital expenditures, working capital and general and administrative expenses.
Lead Product(s): Plasmid DNA-based Therapeutic
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 16, 2022
Details:
ADI-100 consists of two DNA molecules, which together restore immune tolerance in autoimmune disease and establish tolerance in allogeneic skin transplantation applied in large skin wounds.
Lead Product(s): ADI-100
Therapeutic Area: Immunology Product Name: ADI-100
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2022
Details:
Cellvera holds worldwide rights (except Japan) to a broad spectrum oral antiviral drug targeting COVID-19 and other infectious diseases. Cellvera is focused on developing and commercializing antimicrobial therapies across a broad spectrum infectious diseases including Avigan.
Lead Product(s): Favipiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Avigan
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Cellvera
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 05, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
